['diabetes', 'diabetes mellitus, type 2']
['faster-acting insulin aspart', 'insulin aspart', 'insulin degludec', 'metformin']

        Inclusion Criteria: - Male or female, age equal to or above 18 years at the time of signing
        informed consent. - Diagnosed with type 2 diabetes mellitus for 10 years or longer prior to
        screening (Visit 1). - Treated with a basal-bolus insulin regimen for 1 year or longer
        prior to the day of screening (Visit 1). A basal-bolus insulin regimen is defined as basal
        insulin once or twice daily and bolus insulin analogue taken with meals at least 3 times
        daily. Treatment with premixed insulin or soluble insulin combination is not considered a
        basal-bolus regimen. - Treated with or without oral antidiabetic drugs including extended
        release formulations. - HbA1c 7.0-10.0% (both inclusive) as assessed by central laboratory
        at screening (Visit 1). Exclusion Criteria: - Any of the following: myocardial infarction,
        stroke, hospitalization for unstable angina or transient ischaemic attack within the past
        180 days prior to the day of screening (Visit 1). - Subjects presently classified as being
        in New York Heart Association (NYHA) Class IV. - Planned coronary, carotid or peripheral
        artery revascularisation known on the day of screening (Visit 1). - Treatment with
        injectable GLP-1 receptor agonists in a period of 90 days prior to screening (Visit 1). -
        Anticipated initiation or change in concomitant medications (for more than 14 consecutive
        days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid
        hormones, or corticosteroids).
      